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SUMMARY
Background
Case reports suggest that duloxetine hepatotoxicity may arise, but risk fac-
tors, presenting features and clinical course are not well-described.
Aim
To describe the presenting features and outcomes of seven well-character-
ized patients with suspected duloxetine hepatotoxicity.
Methods
Patients enrolled in the Drug-Induced Liver Injury Network Prospective
Study underwent an extensive laboratory and clinical evaluation to exclude
competing aetiologies of liver injury as well as a standardized assessment
for causality and disease severity.
Results
Between 1 ⁄ 2006 and 9 ⁄ 2009, six of the seven cases of DILI attributed to
duloxetine were assessed as definite or very likely. Median patient age was
49 years, six (86%) were women and the median latency from drug initia-
tion to DILI onset was 50 days. Six patients developed jaundice and the
median peak alanine aminotransferase in the five patients with acute hepa-
tocellular injury was 1633 IU ⁄ L. Ascites developed in one patient and acute
renal dysfunction in two others (29%). All patients recovered without liver
transplantation even though three had pre-existing chronic liver disease.
Liver histology in four cases demonstrated varying patterns of liver injury.
Conclusions
Duloxetine hepatotoxicity developed within 2 months of drug intake and
led to clinically significant liver injury. A spectrum of laboratory, histologi-
cal and extra-hepatic features were noted at presentation.
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INTRODUCTION
Mood disorders such as depression and anxiety disorder
are highly prevalent in the general population1 and are
associated with substantial morbidity and resource utili-
zation.2 Specifically, depression has an estimated lifetime
prevalence of 16% and a 12-month prevalence of 6.6% in
the United States.3 Therefore, it is not surprising that
antidepressants are one of the most commonly used
medications in adults. Although antidepressants have
been classified into several classes based on the mecha-
nism of action, they are typically categorized as ‘first
generation’ (monoamine oxidase inhibitors and tricyclic
antidepressants) or ‘second generation’ [selective seroto-
nin reuptake inhibitors, inhibitors of the reuptake of
both serotonin and norepinephrine (SNRIs), and atypi-
cals that have unique modes of action]. Duloxetine
(Cymbalta; Eli Lilly and Company, Indianapolis, IN,
USA) is one of the newer SNRIs approved in 2004 with
indications for use in the treatment of major depressive
disorder, diabetic neuropathy, fibromyalgia and general-
ized anxiety disorder.4 Duloxetine is currently the second
most commonly prescribed antidepressant with 14.4 mil-
lion prescriptions written in 2008 alone.
Drug-induced liver injury (DILI) from antidepressants
has been reported with several agents, but data regarding
duloxetine-induced liver injury are scant. In a pooled
analysis of 17 615 subjects, the incidence of serum alanine
aminotransferase (ALT) levels >3 times the upper limit of
normal (ULN), >5 ULN and >10 ULN were 1%, 0.5%
and 0.2% respectively.5 Almost all subjects maintained
normal values of alkaline phosphatase and total bilirubin
with no case of jaundice and hepatocellular injury (‘Hy’s
law’) reported.5 However, postmarketing surveillance
identified 406 cases with potential hepatotoxicity from
duloxetine between 8 ⁄ 2004 and 8 ⁄ 2006.6 Of these, 58
cases were considered clinically significant. A careful
review of these cases led to the following observations: (i)
there was no dose-dependent increase in the incidence of
hepatic injury, (ii) a large number of cases occurred
between 2 and 8 weeks of therapy and 74% with onset
within 16 weeks, (iii) 31% had either pre-existing liver
disease or clinical risk factors for liver disease, and (iv)
there were two fatal cases possibly related to duloxetine.6, 7
These cases prompted the manufacturer, to issue a ‘Dear
Health Care Professional’ letter and the product label was
revised to include a warning that duloxetine ‘should ordi-
narily not be prescribed to a patient with substantial alco-
hol use or evidence of chronic liver disease’.
In this article, we report seven well-characterized con-
secutive cases of suspected DILI due to duloxetine
enrolled in the Drug-Induced Liver Injury Network (DI-
LIN) Prospective Study. Our aim is to describe their pre-
senting clinical and laboratory features, potential risk
factors and short-term outcomes.
METHODS
Seven subjects enrolled into the DILIN Prospective Study
with suspected liver injury attributed to duloxetine were
identified between 1 ⁄ 2006 and 9 ⁄ 2009. The DILIN Pro-
spective Study was approved by the IRB at all participat-
ing sites. All eligible subjects provided written informed
consent and were required to meet predefined eligibility
criteria including being seen within 6 months of DILI
onset.8 At enrolment, a thorough evaluation was per-
formed to assess for any competing or co-existing cause
of liver injury. All clinical and laboratory data were rec-
onciled with the source documents prior to the causality
assessment as previously described.8 Briefly, all cases
were scored by expert consensus opinion on a scale of 1
(Definite) to 5 (Unlikely). For the current analysis, a sin-
gle reviewer (JHH) independently calculated Roussel
Uclaf Causality Assessment Method (RUCAM) and




A 37-year-old Caucasian man presented with a 2-day
history of nausea, vomiting, upper abdominal pain,
myalgia and flu-like symptoms 6 weeks after starting
duloxetine [60 mg once daily] for depression. Medical
history included chronic alcoholism, hypothyroidism,
obesity and bipolar disorder. Concomitant medications
included levothyroxine, fluoxetine and aripiprazole. He
denied use of acetaminophen, over the counter (OTC)
medications or herbal and dietary supplements (HDS).
He had no history of liver disease, but he reported his
average alcohol consumption as 6–7 drinks per day,
3–4 times ⁄ week for many years. Physical examination
revealed jaundice and mild right upper quadrant
abdominal tenderness. No rash, fever or signs of
chronic liver disease were observed. Initial laboratory
tests showed a total bilirubin of 5.7 mg ⁄ dL, alkaline
phosphatase (Alk P) 175 U ⁄ L, aspartate aminotransfer-
ase (AST) 7500 U ⁄ L and ALT 10 000 U ⁄ L. The white
blood cell count was normal with 4% eosinophils and
international normalized ratio (INR) was elevated at
1.7, but serum albumin was normal (4.1 g ⁄ dL). Tests
for viral hepatitis, serum auto-antibodies and abdominal
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imaging showed no evidence for a competing diagnosis
(Table 1). Serum acetaminophen levels at admission
were undetectable, and acetaminophen-cysteine protein
adducts were not detected from a sample obtained
within 12 h after presentation.9 A transjugular liver
biopsy showed extensive, predominantly zone-3 liver
necrosis and moderate-to-marked steatosis associated
with polymorphonuclear cells with a relatively small
number of mononuclear cells (Figure 1). Mallory bodies
were not seen.
Duloxetine was discontinued and symptoms and labo-
ratory abnormalities improved rapidly over the next
2 weeks (Figure 2). However, serum creatinine was
7.3 mg ⁄ dL on admission and rose to 12.3 mg ⁄ dL, even-
tually requiring temporary haemodialysis. He was dis-
charged after more than a week in hospital and when
seen in follow-up, 6 weeks after onset, he was asymp-
tomatic, had resumed therapy with levothyroxine, fluoxe-
tine and aripiprazole and all liver and kidney tests were
normal.
Comment. This patient presented with severe hepatic
necrosis and renal failure resembling toxic liver injury
such as one that occurs with acetaminophen overdose.
However, he denied use of analgesics and acetaminophen
levels and adducts were not detected. The history of
excessive alcohol use may have contributed to the sever-
ity of illness and affected the liver histology (accounting
for steatosis and polymorphonuclear cell infiltrates), but
the clinical course and liver biopsy were not compatible
with acute alcoholic hepatitis alone. The DILIN causality
score was ‘definite’ and the RUCAM score was 9 (‘highly
Table 1 | Select clinical characteristics of cases with
liver injury after exposure to duloxetine
Clinical characteristics Total (n = 7)
Demographics
Median age (25th, 75th), years 49 (43, 54)
Female gender 6 (86%)
Self-reported race
White or Caucasian 6 (86%)
Black or African American 1 (14%)
Median BMI (25th, 75th) (kg ⁄m2) 32.3 (28.4, 33.1)
Pre-existing medical conditions
Underlying liver disease 2
Prior drug allergies 3 (43%)
Alcohol use 1 (14%)
Diabetes ⁄ endocrine disorder 1 (14%)
Neurological disease 3 (43%)
Congestive heart failure 0
Chronic renal disease 0
Dosage, mg ⁄ day
60 5 (71%)
30 2 (29%)
Median duration of exposure
(25th,75th), days
46 (32, 57)
Latency period, Median (25th,75th), days
Onset of symptoms 50 (34, 59)
Onset of lab abnormalities 50 (35, 56)







Median absolute eosinophils per mm3
(25th,75th)
128 (120–354)
Positive auto-antibodies 3 (43%)
Other organ dysfunction
Acute renal dysfunction 2 (29%)
Altered mental status 1 (14%)
Thrombocytopaenia 1 (14%)
Figure 1 | Liver biopsy of subject # 1. Sections of the
liver with H&E stain viewed under light microscopy and
high power field showed centrilobular coagulative
necrosis and marked fatty change. Inflammatory infil-
trate is predominantly polymorphonuclear and relatively
small number of mononuclear cells. The interlobular bile
ducts were unremarkable.
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probable’). The DILIN severity score was ‘severe’ (4)
(Table 2).
Patient 2
A 29-year-old Caucasian woman with chronic leg and
back pain on long-term oxycodone and ibuprofen was
started on duloxetine [60 mg ⁄ day] as adjuvant therapy
for pain. One month later, she stopped duloxetine
because of symptoms of fatigue, which she attributed to
the medication. Two weeks later, she continued to have
fatigue and had developed nausea, abdominal pain and
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Figure 2 | Biochemical profile
and clinical course of liver
injury of all seven subjects.
Liver biochemistries include
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fluids and intravenous ciprofloxacin and was sent home
on oral ciprofloxacin; 2 days later, she was hospitalized.
She had been taking oxycodone, ibuprofen and birth
control pills for several years. She did not drink alcohol
and denied a history of liver disease or recent use of
acetaminophen-containing products, OTC or herbal
products. Blood tests showed total bilirubin of
1.8 mg ⁄ dL, Alk P 109 U ⁄ L, AST 2586 U ⁄ L, and ALT
3557 with INR of 2.0 and serum creatinine of
2.3 mg ⁄ dL. Serum acetaminophen levels were negative.
The serum antinuclear antibody (ANA) titre was 1:640,
but smooth muscle antibody, immunoglobulin levels
were normal, tests for hepatitis A, B and C were nega-
tive, and imaging showed no evidence for biliary
obstruction (Table 1). With supportive care, she experi-
enced rapid clinical and laboratory improvement within
a month of initial testing except for the ANA, which was
still positive (Figure 2). She restarted oxycodone and ibu-
profen therapy.
Comment. This patient presented with severe acute
hepatic necrosis with renal injury approximately
3 weeks after stopping a 1-month course of duloxetine.
The recent exposure to ciprofloxacin provided another
possible cause of liver injury, but her symptoms pre-
dated the administration of this agent. The DILIN cau-
sality score was 2 ‘very likely’. The RUCAM score was
5 (probable) and the DILIN severity score was 4
(Table 2).
Patient 3
A 49-year-old Caucasian woman with presumed non-
alcoholic fatty liver disease developed nausea, vomiting,
abdominal pain and anorexia 4 weeks after starting dul-
oxetine [30 mg daily]. She consumed clonazepam long-
term and also took low doses of acetaminophen (<1 g
daily) for several days before admission. She denied a
previous history of liver disease, alcohol use, OTC or
HDS. She had undergone gastric bypass surgery for obes-
ity 14 years previously, and was initially thought to have
small bowel obstruction. On examination, she was found
to be jaundiced, dehydrated and had marked abdominal
tenderness. Laboratory tests showed a total bilirubin of
10.8 mg ⁄ dL, Alk P 259 U ⁄ L, AST 467 U ⁄ L and ALT
1437 U ⁄ L. The INR was 2.0 and blood counts showed
thrombocytopaenia (33 000 ⁄ mm3). Acetaminophen levels
were 7.2 lg ⁄ mL (low normal range). Tests for hepatitis
A, B and C were negative as were smooth muscle and
antinuclear antibodies. A small bowel series showed no
evidence of obstruction. Duloxetine was discontinued on
admission and liver test abnormalities began to improve
rapidly (Figure 2). She was discharged within 4 days due
to improvement in liver tests, but was readmitted to
another hospital 10 days later because of abdominal dis-
tension. Abdominal ultrasound demonstrated an
enlarged liver with increased echogenicity and ascites,
but no evidence of biliary obstruction and a normal
spleen size. Serum bilirubin had fallen to 2.2 mg ⁄ dL and
INR to 1.2 and the platelet count had risen to
149 000 ⁄ mm3. A liver biopsy showed steatohepatitis and
bridging hepatic fibrosis, but not frank cirrhosis. An
MRCP showed no evidence of biliary obstruction. She
was treated with diuretics and her ascites ultimately
improved. When seen in follow-up 2 years later, she no
longer required diuretics and liver tests were normal.
Comment. This patient appeared to have an episode of
acute hepatic necrosis superimposed upon presumed
non-alcoholic steatohepatitis (NASH), which led to hepa-
tic decompensation. The DILIN causality score was 2
‘very likely’, RUCAM score was 8 and DILIN severity
score was 4 (jaundice and hepatic decompensation)
(Table 2).
Patient 4
A 56-year-old Caucasian woman with depression and
sciatica was started on duloxetine [30 mg ⁄ day] for pain












1 1 9 4
2 1 8 3
3 2 8 4
4 2 5 3
5 2 7 3
6 4* (possible) 8 1
7 2 6 2
The DILIN causality score ranges from 1 to 5 [3 – probable; 5
– unlikely]. The DILIN severity of the DILI episode is catego-
rized on a scale of 1 (mild) to 5 (fatal resulting in death or
liver transplantation).
DILIN, Drug-Induced Liver Injury Network; RUCAM, Roussel
Uclaf Causality Assessment Method.
* Narrative for case 6 for reasons resulting in assignment of
causality score of 4.
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control. Nine days later, the dose was increased to
60 mg ⁄ day. Approximately 9 weeks later, she presented
with chest pain, non-specific abdominal discomfort and
nausea. She had taken multiple medications for low back
pain in the past, but for the previous several weeks, was
only taking oxycodone, prednisone and low doses of
acetaminophen. She denied use of alcohol, OTC, or
HDS. Her physical examination was largely unremark-
able except for jaundice. A comprehensive inpatient car-
diac evaluation identified no evidence of myocardial
ischaemia or dysfunction. Initial blood tests showed total
bilirubin of 7.6 mg ⁄ dL, Alk P 384 U ⁄ L, AST 114 U ⁄ L
and ALT 179 U ⁄ L. Tests for viral hepatitis and auto-
antibodies were negative, and abdominal imaging identi-
fied no evidence for biliary obstruction (Table 1). The
prothrombin time was normal (INR 0.9) and serum
albumin 3.4 g ⁄ dL. A liver biopsy showed marked portal
infiltrates composed of activated lymphocytes, which
breached the limiting plates. There was also lymphocytic
lobular infiltrates in a sinusoidal pattern, with a ‘pseudo-
mononucleosis’ pattern, but stains for EBV antigens were
negative. Kupffer cells appeared activated and rare foci
of necrosis were seen as well as mild macro- and med-
ium droplet fat. Endothelitis was present in central and
portal venules. (Figure 3a,b). Trichrome stain failed to
reveal significant fibrosis. Duloxetine was stopped upon
admission and symptoms and laboratory tests began to
improve after 4 or 5 days, normalizing over the next
5 weeks (Figure 2).
Comment. This patient presented with a cholestatic hep-
atitis slightly more than 2 months after starting duloxe-
tine. No other cause of acute liver injury was
identified and the subsequent course was typical for a
drug-induced cholestatic injury. DILIN causality score
was 1 as ‘definite’, RUCAM score was 8 and severity
grade 3 (jaundice and hospitalization without hepatic
failure) (Table 2).
Patient 5
A 49-year-old Caucasian woman developed nausea, fati-
gue, dark urine and itching followed by jaundice and
weight loss, 5 weeks after starting duloxetine (60 mg
daily) for chronic pain and depression. She had no his-
tory of liver disease and denied use of alcohol, acetami-
nophen, OTC, or HDS. Physical examination showed
jaundice, without fever, rash or signs of chronic liver dis-
ease. Laboratory testing showed a total bilirubin of
8.3 mg ⁄ dL, Alk P 317 U ⁄ L, AST 103 U ⁄ L and ALT
245 U ⁄ L. Serum acetaminophen levels were undetectable.
Tests for viral hepatitis were negative as was ANA, but
low levels of antismooth muscle antibody were detected
(32 units; normal <30 units). Serum immunoglobulin
levels were normal. Duloxetine was stopped on admis-
sion, but she remained jaundiced, and serum bilirubin
rose to 16.7 mg ⁄ dL with a cholestatic pattern of serum
enzyme elevations (Figure 2). Repeat imaging studies
showed no evidence of biliary obstruction and a liver
biopsy showed intrahepatic cholestasis without bile duct
injury or loss (Figure 4a,b). There was no fibrosis and
scant portal inflammation or evidence of chronic hepati-
tis. Jaundice persisted for more than 2 months, but ulti-
mately resolved. During long-term follow-up, however,
she continued to have mild elevations in serum Alk P
(153 U ⁄ L, 2 years after onset).
Comment. This patient developed a prolonged and
symptomatic cholestatic hepatitis, which progressively
(a) (b)
Figure 3 | Liver Biopsy of subject # 4. Sections of the liver with H&E stain viewed under light microscopy and high
power field. (a) The lobules showed marked inflammatory infiltrate which consisted of necroinflammatory foci as well
as prominent infiltration of sinusoids by lymphocytes. (b) A heavy lymphocytic inflammatory infiltrate was present in
portal tracts and this infiltrate breached the limiting plate. Endothelitis was seen and the bile ducts were preserved.
Duloxetine hepatotoxicity
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worsened for several weeks even after stopping her 1-
month course of duloxetine. DILIN causality score was 2
‘very likely’ RUCAM score was 7 (‘probable’) and sever-
ity score was 3 (jaundice and hospitalization) (Table 2).
Patient 6
A 58-year-old African-American woman with chronic
hepatitis C, diabetes, obesity, gout, chronic anxiety and
chronic low back pain had duloxetine [30 mg daily]
added to a chronic regimen of amitriptyline, clonazepam,
oxycodone, propranolol, allopurinol, colchicine and acet-
aminophen. Two weeks later, she was brought to the
emergency room after being found unresponsive at
home. She was stuporous, but vital signs were stable. She
was admitted to the intensive care unit and started on
antibiotics for suspected meningitis and levetiracetam for
persistent obtundation. A toxicology screen showed the
presence of benzodiazepines and opiates, but no alcohol.
Initial laboratory tests showed minimal liver test abnor-
malities with total bilirubin 0.6 mg ⁄ dL, Alk P 71 U ⁄ L,
AST 81 U ⁄ L and ALT 42 U ⁄ L. Duloxetine was given
intermittently, but was stopped when serum enzymes
rose (ALT 125 U ⁄ L, AST 289 U ⁄ L, Alk P 78 U ⁄ L).
Serum aminotransferase levels peaked several days later
and then began to fall (Figure 2). Duloxetine was
restarted, but held again when ALT levels rose from 310
to 654 U ⁄ L and AST from 390 to 1269 U ⁄ L, thereafter
falling to normal. Tests for hepatitis A and hepatitis B
were negative. She was positive for both antibody to
HCV and HCV RNA, which she was known to have had
for several years. Imaging of the liver by ultrasound and
CT scan showed a normal appearing liver and spleen
and no evidence of biliary obstruction. After 3 weeks in
the hospital, her sensorium had cleared and serum
enzymes had fallen to near normal levels (ALT 61 U ⁄ L,
AST 39 U ⁄ L) (Figure 2) and she was discharged.
Comment. This patient had an unexplained episode of
confusion and obtundation that occurred 2 weeks after
starting duloxetine. During her hospitalization, restarting
duloxetine was followed by prompt rises in serum ALT
and AST levels, without jaundice. While the timing of
serum enzyme elevations were supportive of the role of
duloxetine in their aetiology, her underlying chronic hep-
atitis C and the multiple medications and procedures
that she underwent during the hospitalization made it
difficult to assign causality to duloxetine alone. DILIN
causality score was 4 ‘possible’, RUCAM score was 8 and
the severity score 1 (serum enzyme elevations without
jaundice) (Table 2).
Patient 7
A 52-year-old Caucasian woman with rheumatoid arthri-
tis and coronary artery disease developed nausea, vomit-
ing and abdominal pain 8 weeks after starting duloxetine
[60 mg daily]. She was also taking methotrexate (started
3 years previously) and monthly infliximab infusions (for
the previous 4 months). She had no history of liver dis-
ease, had normal liver tests on methotrexate and did not
drink alcohol or take OTC or HDS. Physical examination
was unremarkable; she was anicteric and afebrile. Labo-
ratory testing showed total bilirubin of 0.8 mg ⁄ dL, Alk P
203 U ⁄ L, AST 719 U ⁄ L and ALT 996 U ⁄ L. Tests for
hepatitis A, B, and C were negative and auto-antibodies
were not present. An ultrasound showed no evidence of
(a)
(b)
Figure 4 | Liver Biopsy of subject # 5. (a) Only minimal
portal and lobular inflammation was seen. Most portal
areas showed only a few inflammatory cells, mainly
neutrophils and eosinophils (400·, H&E). (b) Canalicu-
lar and hepatocellular cholestasis was easily identified
(arrows) (600·, H&E).
R. Vuppalanchi et al.
1180 Aliment Pharmacol Ther 2010; 32: 1174–1183
ª 2010 Blackwell Publishing Ltd
biliary obstruction. A liver biopsy demonstrated a mild
hepatitis with lobular and portal inflammation and mild
fibrosis. The dose of duloxetine was decreased and she
was started on prednisone [40 mg daily]. Because of a
lack of improvement in liver tests (Figure 2), duloxetine
was discontinued 22 days after initial presentation,
whereupon liver tests rapidly improved.
Comment. This patient presented with an acute hepatitis
like syndrome without jaundice, which was initially not
attributed to duloxetine. After a lack of improvement
and development of mild jaundice, however, duloxetine
was stopped, and liver tests subsequently improved and
were normal during follow-up (total bilirubin 0.6 mg ⁄ dL,
Alk P 48 U ⁄ L, AST 22 U ⁄ L and ALT 22 U ⁄ L approxi-
mately 100 days after the initial event was recognized).
The DILIN causality score was 2 or ‘very likely’, RU-
CAM score was 6 and severity score was 2 (jaundiced
but not hospitalized) (Table 2).
RESULTS
A total of seven subjects were identified in the DILIN
database of approximately 600 sequential cases (1% of
total) with suspected hepatotoxicity from exposure to
duloxetine (Table 1). In six cases, duloxetine was the
only implicated agent and causality rated either definite
(n = 2) or very likely (n = 4). The median age of
patients was 49 years and all except one (86%) were
women (Table 1). The median time to onset of symp-
toms or laboratory abnormalities was 50 days. Five
patients had a hepatocellular pattern of serum enzyme
elevations and two a cholestatic pattern. There were
wide variations in the peak values of liver tests (Table 3).
Skin rash, fever and eosinophilia, and features of immu-
noallergic or autoimmune hepatitis were not common.
All patients showed improvement in their liver test
abnormalities during the follow-up period. Three patients
had underlying chronic liver disease from hepatitis C,
alcoholic liver disease and NASH. In one patient with
underlying chronic liver disease, new onset ascites
was observed. Acute renal insufficiency occurred in
two patients and bone marrow suppression (thrombo-
cytopenia and mild leucopaenia) in one. Four of the
seven cases were considered severe, demonstrating evi-
dence of hepatic failure or accompanying bone marrow
or renal failure, but all patients recovered without liver
transplantation. No deaths were reported during the
study follow-up.
DISCUSSION
Spontaneous reports of hepatic injury from duloxetine
use to the manufacturer and FDA have raised concerns
about the safety of this widely used drug. However,
inherent limitations associated with such a reporting sys-
tem makes causality assessment difficult and inconclusive
due to incomplete information. An identifiable clinical
signature and pattern of liver injury often cannot be rec-
ognized from such scant data. To date, there is only one
published case report of duloxetine hepatotoxicity.7 In
this report, the investigators described various tests
including serology, imaging and liver biopsy to make an
argument for duloxetine hepatotoxicity. Unfortunately,
this patient also received concomitant mirtazapine mak-
ing the case less compelling. The current series of seven
patients with liver injury after exposure to duloxetine
provides a more detailed description of presentations









P (U ⁄ L)
Time to improve by ‡50%
from peak (days)
ALT T.Bili Alk P
1 Hepatocellular 6.1 10 000 175 3 13 41
2 Hepatocellular 2.3 3557 109 4 5 –
3 Hepatocellular 10.8 467 259 2 4 15
4 Cholestatic 12.2 265 468 21 4 18
5 Cholestatic 16.7 245 397 6 50 50
6 Hepatocellular 3.4 654 92 3 5 –
7 Hepatocellular 2.9 1633 203 11 8 –
T.Bili, total bilirubin; ALT, alanine aminotransferase; Alk P, alkaline phosphatase.
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and outcomes of liver injury associated with this agent.
These seven cases were enrolled between 2006 (2 years
after FDA approval) and 2008 at three sites participating
in the DILIN prospective study. The prospective nature
of the study design and use of standardized case report
forms for data capture ensured a uniformly high data
capture rate and exclusion of competing causes of liver
injury. The use of ‘expert consensus’ opinion for causal-
ity assessment not only ensured a thorough evaluation to
exclude competing aetiologies conclusively but also
addressed the issue of widespread variability in RUCAM
scores assigned by different reviewers.10 In the six cases
attributed to duloxetine alone in our series, all of them
were scored as definite or highly likely while the one case
with multiple suspect drugs had a score of ‘possible’ dul-
oxetine hepatotoxicity.
Several observations from this case series merit atten-
tion. Hepatotoxicity from duloxetine appears to be more
common at a daily dose of 60 mg compared with 30 mg
(5 vs. 2 respectively). It is noteworthy that six of the
affected patients were women, raising the possibility that
female gender might be a risk factor for developing
severe duloxetine hepatotoxicity. The onset of symptoms
of liver injury averaged 6–7 weeks after staring the drug.
Features of hypersensitivity (rash, fever and eosinophilia)
and autoimmunity were not prominent. Three patterns
of hepatic injury occurred; three patients had severe
acute hepatic necrosis with a precipitous rise in serum
aminotransferase levels, damage to other organs (bone
marrow or kidney) and rapid recovery; two patients had
a cholestatic hepatitis; and two had serum ALT and AST
elevations with no or minimal jaundice. Of particular
significance is, two patients with acute hepatic necrosis
developed concurrent evidence of acute renal injury and
one required haemodialysis. Therefore, duloxetine hepa-
totoxicity may be severe at presentation.
Based on postmarketing adverse event reports, alcohol
abuse and pre-existing chronic liver disease have been
cited as potential risk factors for duloxetine hepatotoxic-
ity. Underlying liver disease has also been implicated in
patients with isoniazid and antiretroviral hepatotoxic-
ity.11–14 In this case series, one patient admitted to sig-
nificant alcohol consumption and two others appeared to
have underlying chronic liver disease (one with NASH
and with chronic hepatitis C). The patient with NASH
developed signs of acute liver decompensation with new
onset ascites and jaundice. All patients showed improve-
ment in their liver test abnormalities during the follow-
up period and none required liver transplantation. No
death was reported during the study follow-up.
Patients with underlying liver disease may be at
increased risk of developing DILI due to increased intra-
hepatic immune activity, altered drug toxification ⁄ detoxi-
fication pathways, etc. As patients with mood disorders
frequently have underlying liver disease, a careful consid-
eration of the risk vs. benefit of duloxetine in patients
with liver disease is recommended. As a minimum,
assessing baseline liver biochemistries would be advisable
as well as repeat laboratory monitoring during the first
12–16 weeks of duloxetine therapy. In addition, a careful
and slow titration of the duloxetine dose would be advis-
able particularly in patients with pre-existing liver dis-
ease. The lack of hypersensitivity features noted in our
series does not entirely exclude an immunological mech-
anism in duloxetine hepatotoxicity, as was recently
shown with flucloxacillin hepatoxicity.15 Therefore, col-
lection of DNA samples from well-characterized cases
like these enrolled in the DILIN study and other regis-
tries around the world may allow for future mechanistic
investigation of the potential role of host genetic factors
in these rare adverse events.
In summary, duloxetine-induced liver injury appears
to be idiosyncratic in nature and its onset is within
2 months after its initiation. Several patterns of hepatic
injury (signatures) occur, including hepatocellular and
cholestatic features. The available liver histology is highly
variable. Acute kidney failure or other organ involvement
may occur. The hepatic injury can be severe, although
full recovery is the usual outcome. This report raises the
possibility that duloxetine administered at 60 mg ⁄ day is
more hepatotoxic than 30 mg daily dose. The relation-
ship between duloxetine hepatotoxicity and underlying
liver disease and female gender requires further investi-
gation. Physicians using this drug should be aware of the
spectrum of liver injury and consider duloxetine as
another agent capable of causing life-threatening liver
injury. In patients with underlying liver disease, slow and
deliberate dosage titration with careful monitoring for
adverse hepatic effects in the first few months of duloxe-
tine therapy is suggested.
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